Related Experiment Videos
Primary embryonal carcinoma of the retroperitoneum
1Department of Internal Medicine, Hiratsuka City Hospital, Kanagawa, Japan.
Internal Medicine (Tokyo, Japan)
|April 1, 1993
Summary
Primary retroperitoneal embryonal carcinoma, a rare cancer, rapidly progressed but responded well to cisplatin, vinblastine, and bleomycin (PVB) chemotherapy. This treatment showed remarkable tumor regression and no recurrence after two years.
Area of Science:
- Oncology
- Urology
Background:
- Primary retroperitoneal embryonal carcinoma is an exceptionally rare germ cell tumor.
- Embryonal carcinoma typically originates in the testes, making extragonadal occurrences notably infrequent.
Observation:
- A 32-year-old male presented with acute progression of retroperitoneal embryonal carcinoma.
- Clinical presentation included rapid enlargement of cervical and inguinal lymph nodes.
- Elevated serum markers, specifically alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG), were detected, despite intact testes.
Findings:
- Systemic combination chemotherapy using cisplatin, vinblastine, and bleomycin (PVB) induced significant tumor regression.
- The patient experienced no recurrence of the disease in the two years following treatment.
Implications:
- PVB therapy demonstrates efficacy in managing advanced or rare presentations of embryonal carcinoma.
- This case highlights the potential for successful treatment of extragonadal germ cell tumors with established chemotherapy regimens.
- Early diagnosis and prompt chemotherapy are crucial for favorable outcomes in rare embryonal carcinoma cases.